Holen Sie sich die Stockscreener-App
5.06
19.62%
0.83
Vorhandelsmarkt:
4.83
-0.23
-4.55%
Schlusskurs vom Vortag:
$4.23
Offen:
$4.55
24-Stunden-Volumen:
1.28M
Relative Volume:
14.88
Marktkapitalisierung:
$431.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.64M
KGV:
-11.77
EPS:
-0.43
Netto-Cashflow:
$-39.43M
1W Leistung:
+30.41%
1M Leistung:
+29.08%
6M Leistung:
+63.75%
1J Leistung:
+67.00%
1-Tages-Spanne:
$4.32
$5.07
1-Wochen-Bereich:
$3.84
$5.07
52-Wochen-Spanne:
$2.30
$5.07
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Firmenname
Alpha Tau Medical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie DRTS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
5.06 | 360.67M | 0 | -29.64M | -39.43M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-04-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-04-08 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-04 | Eingeleitet | Citigroup | Buy |
Alpha Tau Medical Ltd Aktie (DRTS) Neueste Nachrichten
Taking on analysts’ expectations and winning: Alpha Tau Medical Ltd (DRTS) - Setenews
Alpha Tau Medical Just Treated Its First Brain Tumor Patient – and It Could Mark an Inflection Point for the Company (NASDAQ: DRTS) - markets.businessinsider.com
H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock - Investing.com
Promising Clinical Developments and Innovative Technology Drive Buy Rating for Alpha Tau Medical Ltd - TipRanks
Alpha Tau price target lowered to $7 from $8 at Citi - TipRanks
Optimistic Growth Prospects and Strategic Developments Drive Buy Rating for Alpha Tau Medical Ltd - TipRanks
Alpha Tau Treats First U.S. Brain Cancer Patient With Alpha DaRT; Shares Surge On Breakthrough - Nasdaq
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
Study: Alpha Tau Successfully Treats First Patient with Recurrent Glioblastoma - Imaging Technology News
Alpha Tau Medical Ltd. Successfully Treats First Patient in Its U.S. Trial for Patients with Recurrent Glioblastoma At the James Cancer Hospital At the Ohio State University - marketscreener.com
Alpha Tau announces first patient treated in study using Alpha DaRT tech - TipRanks
Alpha Tau Treats First U.S. Patient with Alpha DaRT for Glioblastoma - TipRanks
Alpha Tau (Nasdaq: DRTS) gives first Alpha DaRT brain treatment in OSU GBM study - Stock Titan
Alpha Tau Medical (NASDAQ:DRTSW) Trading 6.9% Higher – Here’s What Happened - Defense World
Will Alpha Tau Medical Ltd. Equity Warrant stock outperform international peersMarket Risk Analysis & Real-Time Volume Trigger Notifications - Newser
Is Alpha Tau Medical Ltd. Equity Warrant stock a smart buy before Fed meeting2025 Technical Overview & Reliable Breakout Forecasts - Newser
Why Alpha Tau Medical Ltd. Equity Warrant stock is popular among millennialsMarket Risk Analysis & Low Risk Investment Opportunities - Newser
Will Alpha Tau Medical Ltd. stock rally after Fed decisionsJuly 2025 Outlook & Stock Portfolio Risk Management - Newser
Alpha Tau announces two Alpha DaRT abstracts at ASCO Symposium - TipRanks
Alpha Tau Medical to Present Pancreatic Cancer Research at 2026 ASCO Symposium - TipRanks
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium - The Manila Times
Alpha Tau Announces Presentation of Two Alpha DaRT - GlobeNewswire
How Alpha Tau Medical Ltd. stock benefits from global expansionMarket Sentiment Summary & Risk Adjusted Buy/Sell Alerts - Newser
Alpha Tau Medical Ltd. Receives FDA Approval to Initiate A Trial for Patients with Locally Recurrent Prostate Cancer - marketscreener.com
Alpha Tau receives FDA approval to initiate a trial for patients with locally recurrent prostate cancer - marketscreener.com
Alpha Tau Medical Receives FDA Approval for Prostate Cancer Trial - TipRanks
Alpha Tau receives FDA approved IDE application to initiate study of Alpha DaRT - TipRanks
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer - The Manila Times
Alpha Tau (NASDAQ: DRTS) gains FDA IDE to test Alpha DaRT in recurrent prostate cancer - Stock Titan
Alpha Tau to Participate in December Investor Conferences - The Manila Times
COO Gat Files To Sell 16,000 Of Alpha Tau Medical Ltd [DRTS] - TradingView
Alpha Tau (NASDAQ: DRTS) to present at Piper Sandler, Sidoti investor events in Dec 2025 - Stock Titan
What insider trading reveals about Alpha Tau Medical Ltd. stockJuly 2025 Momentum & Safe Capital Growth Stock Tips - moha.gov.vn
HC Wainwright Has Negative Outlook for DRTS FY2025 Earnings - MarketBeat
What is HC Wainwright’s Forecast for DRTS FY2025 Earnings? - Defense World
Alpha Tau Medical (NASDAQ:DRTS) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms Buy Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Promising Developments and Strategic Trials Support Buy Rating for Alpha Tau Medical Ltd. - TipRanks
Alpha Tau Medical Reports Q3 2025 Progress and Financials - MSN
Alpha Tau reports Q3 EPS (32c), consensus (12c) - MSN
Alpha Tau Eyes Year-End Japanese Clearance For Alpha DaRT Treatment In Recurrent Head & Neck Cancer - Nasdaq
Alpha Tau Medical Reports Q3 2025 Results and Advances in Cancer Therapy - TipRanks
[6-K] Alpha Tau Medical Ltd. Current Report (Foreign Issuer) | DRTS SEC FilingForm 6-K - Stock Titan
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
How sustainable is Alpha Tau Medical Ltd. Equity Warrant stock dividend payoutMarket Sentiment Report & Technical Analysis for Trade Confirmation - newser.com
How Alpha Tau Medical Ltd. Equity Warrant stock performs in high volatility marketsJobs Report & Daily Entry Point Trade Alerts - newser.com
How Alpha Tau Medical Ltd. Equity Warrant stock responds to policy changesMarket Performance Summary & Capital Protection Trading Alerts - newser.com
Is Alpha Tau Medical Ltd. stock a defensive play in 2025Trade Analysis Report & Risk Controlled Daily Trade Plans - newser.com
Applying Elliott Wave Theory to Alpha Tau Medical Ltd. Equity WarrantJuly 2025 Earnings & Real-Time Sentiment Analysis - newser.com
Relative strength of Alpha Tau Medical Ltd. in sector analysis2025 Bull vs Bear & Momentum Based Trading Signals - newser.com
Finanzdaten der Alpha Tau Medical Ltd-Aktie (DRTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):